IL6 and autoimmune disease: Considering several IL-6 inhibitors are currently available in clinical use for treating inflammatory and autoimmune diseases, such as tocilizumab, sarilumab, and satralizumab, the presented IL-6-meidated mechanism in our data might suggest the potential translational values of these IL-6 inhibitors in cancer treatment.